The Best of the SOLACI-SOCIME 2022 Main Arena: Structural—Selected Topics of TAVR

On the last session from day 1 of SOLACI-SOCIME 2022 on structural pathology, Dr. Raj Makkar, an international expert on the subject, talked about transcatheter aortic valve replacement (TAVR) in pure aortic regurgitation (AR), which presents several implantation challenges, such as insufficient anchoring, embolization, residual regurgitation, ring rupture, etc. 

As opposed to patients with aortic stenosis, patients with AR had a higher migration index, more transcatheter reintervention, and greater surgical reintervention.

Additionally, only 25% of patients with severe AR are treated in the US, which shows us that this is an undertreated population. While using devices developed for aortic stenosis is accepted, they are off-label for AR, as they are not ideal for its anatomy, which opens up an opportunity to test specific devices.

Dr. Raj Makkar (USA)

Later, Dr. Ole De Backer (DEN) addressed the clinical implications of imaging findings, such as reduced leaflet motion or their hypoattenuation (HALT).

Through tomographic studies with adequate follow-up, these issues might not impact transvalvular gradient, thromboembolic events, or mortality. The only affected parameter was eventual long term durability (hypothesis).

He discouraged the systematic search for this problem; it should only be suspected in patients with a mean gradient >10 mmHg, early degeneration, or a neurological event unrelated to another cause.

Dr. Ole de Backer (DNK)
Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...